Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

Psychiatry Research

Volumn 101, Issue 3, 2001, Pages 277-288

  Fontaine, Kevin R ^a   Heo, Moonseong ^b   Harrigan, Edmund P ^c   Shear, Charles L ^c   Lakshminarayanan, Mani ^c   Casey, Daniel E ^d   Allison, David B ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Atypical antipsychotics; Obesity; Weight gain

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION; PRIORITY JOURNAL; SEX RATIO; SMOKING; SUICIDE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; HUMANS; HYPERGLYCEMIA; HYPERTENSION; MODELS, STATISTICAL; MORTALITY; OBESITY; RISK; SCHIZOPHRENIA; UNITED STATES; WEIGHT GAIN;

EID: 0035871492     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(01)00234-7     Document Type: Article

References (42)

1. Obesity treatment: Examining the premises
2. Antipsychotic-induced weight gain: A comprehensive research synthesis
3. Annual deaths attributable to obesity in the United States
4. The distribution of body mass index among individuals with and without schizophrenia
5. Safety of olanzapine
6. Means at each examination and inter-examination variation of specified characteristics: Framingham Heart Study
7. Causes of the excess mortality of schizophrenia
8. Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?
9. Weight gain and prescription medications: A review
10. Risperidone use at a state hospital: A clinical audit 2 years after the first wave of risperidone prescriptions
11. Epidemiological background and design: The Framingham Study
12. Epidemiological approaches to heart disease: The Framingham Study
13. Mental disorders and use of cardiovascular procedures after myocardial infarction
14. Olanzapine for Schizophrenia
15. Overweight and obesity in the United States: Prevalence and trends, 1960-1994
16. Clozapine and body mass change
17. Prospective study of intentionality of weight loss and mortality in older women: The Iowa Women's Health Study
18. Weight gain associated with antipsychotic drugs
19. Beneficial effects of modest weight loss
20. Excess mortality of mental disorder
21. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
22. New atypical antipsychotic medications
23. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
24. Swedish obese subjects (SOS): An obesity intervention study with a nutritional perspective
25. Body weight and mortality among women
26. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
27. Suicide in schizophrenia: The effect of clozapine
28. Mortality in a cohort of patients with schizophrenia: A record linkage study
29. Time trends in schizophrenia mortality in Stockholm County Sweden: A cohort study
30. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity
31. NHLBI Obesity Education Initiative Expert Panel on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report
32. The treatment of unrelated disorders in patients with chronic medical diseases
33. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder
34. Anthropometry and adiposity in a group of people with chronic mental illness
35. The distribution of adipose tissue in female in-patients receiving psychotropic drugs
36. The relationship between body weight and mortality: A quantitative analysis of combined information from existing studies
37. Newer atypical antipsychotic medication versus clozapine for schizophrenia
38. Clozapine versus typical neuroleptic medication for schizophrenia
39. Novel antipsychotics: Comparison of weight gain liabilities
40. Report of a National Institutes of Health - Centers for Disease Control and Prevention workshop on the feasibility of conducting a randomized clinical trial to estimate the long-term health effects of intentional weight loss in obese persons